Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

Validation Study of Simplified Chinese Version of LOTCA Scale in the Assessment of Cognitive Impairment in Patients with Traumatic Brain Injury

NCT06850584 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing Broad Biopharmaceutical Ltd
Phase
Observational
Started
2025-03-01
Last updated
2025-02-27

Condition(s) studied

Traumatic Brain Injury

Investigational drug(s) / intervention(s)

Observation

Observation: The study was observational and did not involve any intervention.

Study summary

In this study, 300 patients aged ≥18 years old with traumatic brain injury (case group) and hospitalized patients without central nervous system disease or their family members and accompanying staff (control group) were selected as the study objects. At baseline, participants completed the Mini-mental State Examination (MMSE), the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery, the Glasgow Coma Scale (GCS), and the Alzheimer's Disease Rating Scale Cognitive Subscale (ADAS-Cog11). The evaluation process of the first LOTCA test was videotaped by a person. 2 weeks after the evaluation, the same two scale raters watched the video and rated it independently again. After 3 months, the subjects completed MMSE, LOTCA battery, GCS, ADAS-Cog11 assessment again.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: \- Case group: Patients with traumatic brain injury Inclusion Criteria: 1. Age\> = 18 years old, male or female; 2. patients with traumatic brain injury; 3. The Mini-Mental State Examination (MMSE) score was lower than normal, and the cut-off value for diagnosis was determined according to different education levels: illiteracy (uneducated) \<=19 points, primary school level \<=22 points, junior high school level and above \< = 26 points; 4. Voluntary participation and ability to complete the study and sign the informed consent form in accordance with the requirements of the study protocol. Control group: family members or accompanying persons of patients in the same period Inclusion Criteria: 1. Age\> = 18 years old, male or female; 2. recent emotional stability; 3. Mini-Mental State Examination (MMSE) score was normal; 4. Voluntary participation and ability to complete the study and sign the informed consent form in accordance with the requirements of the study protocol. Exclusion Criteria: \- Case group: Patients with traumatic brain injury Exclusion Criteria: 1. The study subject is in a lethargic state, coma, or persistent vegetative state; 2. the disease progresses rapidly or is accompanied by serious complications; 3. The subject has severe language dysfunction or/or bilateral upper limb motor function loss; 4. the study subject has severe visual and/or hearing impairment; 5. The subject has a severe mental disorder, physical weakness or other conditions (such as intolerance to the test or uncooperation, etc.); 6. Those who have a history of drug abuse within 6 months before screening or those who have used drugs within 3 months before screening; 7. Those who are considered by the investigator to be unsuitable to participate in this study or cannot complete this study for other reasons. Control group: family members or accompanying persons of patients in the same period Exclusion Criteria: 1. History of congenital or acquired central nervous system disease (including history of traumatic brain injury, cerebrovascular accident, etc.); 2. Those who have a history of drug abuse within 6 months before screening or who have used drugs within 3 months before screening; 3. Those who are considered by the investigator to be unsuitable to participate in this study or cannot complete this study for other reasons.

Primary outcome measure(s)

  • Evaluator Reliability of the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery — At baseline
  • Retest Reliability of the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery — 2 weeks Later
  • Internal Consistency Reliability of the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery — At baseline
  • Content Validity of the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery — At baseline
  • Construct Validity of the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery — At baseline
  • Discriminative Validity of the Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery — At baseline
  • The change of Loewenston Occupational Therapy Cognitive Assessment (LOTCA) battery score from baseline values — 3 months later
  • The change of Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 score from baseline values — 3 months later
  • Correlation between LOTCA score change from baseline and ADAS-Cog11 score change from baseline — 3 months later
  • The area under ROC curve and the sensitivity, specificity and Jorden index under optimal threshold of LOTCA score change from baseline value — 3 months later

Trial sites (4)

FacilityCityRegionStatus
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University Huaian Jiangsu
Suzhou Jiulong Hospital Suzhou Jiangsu
The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu
Northern Jiangsu People's Hospital Yangzhou Jiangsu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06850584 on ClinicalTrials.gov ↗ ← All trials in China